The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
David Pérol
Honoraria - Roche
Isabelle Ray-Coquard
Honoraria - Amgen; Merck; Novartis; PharmaMar; Roche; Sanofi
Research Funding - Merck (B); Novartis; Roche
Binh Bui Nguyen
Honoraria - Novartis; PharmaMar
Antoine Adenis
No relevant relationships to disclose
Maria Rios
No relevant relationships to disclose
François Bertucci
No relevant relationships to disclose
Florence Duffaud
No relevant relationships to disclose
Didier Cupissol
No relevant relationships to disclose
Christine Chevreau
No relevant relationships to disclose
Emmanuelle Bompas
No relevant relationships to disclose
Julien Domont
No relevant relationships to disclose
Sylvie Chabaud
No relevant relationships to disclose
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar